These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15292932)

  • 1. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
    Calvet L; Santos A; Valent A; Terrier-Lacombe MJ; Opolon P; Merlin JL; Aubert G; Morizet J; Schellens JH; Bénard J; Vassal G
    Br J Cancer; 2004 Sep; 91(6):1205-12. PubMed ID: 15292932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
    Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
    Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
    Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
    Santos A; Calvet L; Terrier-Lacombe MJ; Larsen A; Bénard J; Pondarré C; Aubert G; Morizet J; Lavelle F; Vassal G
    Cancer Res; 2004 May; 64(9):3223-9. PubMed ID: 15126363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
    Kaneko S; Ishibashi M; Kaneko M
    Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
    Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
    Calvet L; Geoerger B; Regairaz M; Opolon P; Machet L; Morizet J; Joseph JM; Elie N; Vassal G
    Oncogene; 2006 May; 25(22):3150-9. PubMed ID: 16501609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
    Komuro H; Li P; Tsuchida Y; Yokomori K; Nakajima K; Aoyama T; Kaneko M; Kaneda N
    Med Pediatr Oncol; 1994; 23(6):487-92. PubMed ID: 7935175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
    Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
    Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
    van Hattum AH; Hoogsteen IJ; Schlüper HM; Maliepaard M; Scheffer GL; Scheper RJ; Kohlhagen G; Pommier Y; Pinedo HM; Boven E
    Br J Cancer; 2002 Sep; 87(6):665-72. PubMed ID: 12237778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
    Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
    Kaneko M; Kaneko S; Suzuki K
    Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
    Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
    Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
    Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
    Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
    Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer GL; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JD; Haber M
    Mol Cancer Ther; 2005 Apr; 4(4):547-53. PubMed ID: 15827327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
    Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
    Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.